Review of Cases of Acute Myeloid Leukemia in Elderly Treated at Lehigh Valley Health Network from 2010-2014 by Goetz, Melanie & Skandan, Savitri, MD
Lehigh Valley Health Network
LVHN Scholarly Works
Research Scholars Poster Presentation
Review of Cases of Acute Myeloid Leukemia in





Lehigh Valley Health Network, Savitri.Skandan@lvhn.org
Follow this and additional works at: http://scholarlyworks.lvhn.org/research-scholars-posters
This Poster is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion in LVHN Scholarly Works by an
authorized administrator. For more information, please contact LibraryServices@lvhn.org.
Published In/Presented At
Goetz, M., & Skandan, S. (2016, July, 29). Review of Cases of Acute Myeloid Leukemia in Elderly Treated at Lehigh Valley Health Network
from 2010-2014. Poster presented at LVHN Research Scholar Program Poster Session, Lehigh Valley Health Network, Allentown, PA.
© 2016 Lehigh Valley Health Network
Lehigh Valley Health Network, Allentown, Pennsylvania
Review of Cases of Acute Myeloid Leukemia in Elderly Treated at Lehigh Valley Health Network 
from 2010-2014
• Acute myeloid leukemia (AML) is the most 
common type of acute leukemia among adults and 
causes the largest number of annual deaths from 
leukemias in the United States1.
• Majority of AML patients are elderly, defined as age 
60 and above, with a median age of diagnosis of 
67 years and a 5-year survival range of 5-15%2.
• Advanced age is one of the major prognostic 
factors in AML due to the increase in comorbidities 
and a greater likelihood for unfavorable cytogenetic 
abnormalities3. 
• FLT3 gene encodes for a tyrosine kinase receptor 
involved in hematopoiesis. Elderly patients have a 
higher frequency for the FLT3-ITD mutation, which 
is associated with an increased relapse risk and 
shorter overall survival4. 
• The goals of our study are to determine whether 
treatments offered to elderly AML patients at LVHN 
from 2010-14 were in accordance with the National 
Comprehensive Cancer Network (NCCN) 
Guidelines Version 1.2016 and to determine the 
overall survival of elderly AML patients and 
compare survival across risk groups.
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• 137 cases of elderly AML seen by LVHN were 
reviewed. 15 cases did not fit the classification of 
AML and 2 transferred care. These cases were 
excluded from our study, leaving 120 cases to be 
reviewed.
• Age of diagnosis, cancer morphology, presence of 
comorbidities, cytogenetic and molecular testing for 
risk stratification, treatment received, and overall 
survival were determined by reviewing all patient 
transcripts including pathology reports. 
• The National Comprehensive Cancer Network 
Clinical Practice Guidelines in Oncology for Acute 
Myeloid Leukemia Version 1.2016 was referenced 
to compare treatment offered by LVHN to the 
national standard1.
• Treatments offered by LVHN were in accordance 
with the NCCN guidelines and were similar across 
risk status groups1.
• There was about a 13% survival rate, consistent 
with the literature range2. 
• There were no survivors within the poor risk group, 
despite receiving the same treatments as patients 
with more favorable cytogenetics. Clinical trials 
should be encouraged for patients with poor risk 
cytogenetics.
• Potential therapeutic benefit for patients with a 
normal karyotype and FLT3-ITD mutation.











Figure 1. Patient risk status determined by cytogenetic and molecular studies of bone marrow aspirate. Presence of the following 
abnormalities placed a patient in the appropriate risk status: Favorable; inv(16), t(16;16), t(8;21), t(15;17), normal cytogenetics with 
NPM1(+) and FLT3-ITD(-), Intermediate; normal cytogenetics,+8, t(9;11), other non-defined, Poor; complex, monosomal karyotype, -
5, 5q-, -7, 7q-, 11q23, inv(3), t(3;3), t(6;9), t(9;22), normal cytogenetics with FLT3-ITD(+)1.Percent of patients in each risk 
stratification group were as following: favorable, 13%; intermediate, 45%; poor, 23%; not available (N/A), 19%. Patients who did not 




































































Figure 2. Treatment received for elderly patients with AML according to risk status. Percent of patients in each risk status that 
received the following treatments. (Dark Green) supportive care: transfusion support, hydroxyurea, hospice (Dark Blue) 
chemotherapy: single or combination 7+3 (standard-dose cytarabine with an anthracycline), MEC (mitoxantrone, etoposide, Ara-C), 
Vidaza (5-azacytidine), and/or Dacogen (decitabine), (Light Blue) clinical trial, (Light Green) chemotherapy + other treatment 
regiment, either stem cell transplant, clinical trial, or Mylotarg (gemtuzumab).
Figure 3. Survival of AML patients. A. Overall survival, 16 out of 120 patients survived (13%) and 104 expired (87%). B. Overall 




















Presence of FLT3-ITD Mutation in Patients 
with Normal Karyotypes
Figure 4. Frequency of FLT3-ITD mutation among the elderly AML patients whom have 
normal karyotypes. Out of the 120 elderly patients treated at Lehigh Valley Health 
Network from 2010-2014, 97 patients had cytogenetic studies performed. 41 patients had 
normal cytogenetics and 17 patients had additional molecular studies performed. Of the 
17 patients, 5 patients (29%) obtained the FLT-ITD mutation and 12 patients (71%) did 
not. 
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